Acumen Pharmaceuticals, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 0.2101 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 15.20M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer’s disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Details
| Name | Acumen Pharmaceuticals, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 61 |
| Founded | 1996 |
| Ipo Date | 2021-07-01 |
| Ceo | Daniel O'Connell |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 16.00 |
| Isin | US00509G2093 |
| Cusip | 00509G209 |
| Cik | 1576885 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Daniel J. O'Connell M.B.A. | Chief Executive Officer and Director |
| Dr. James Doherty Ph.D. | President and Chief Development Officer |
| Matt Zuga | Chief Financial Officer and Chief Business Officer |
| Dr. Grant A. Krafft Ph.D. | Co-Founder |
| Dr. Caleb E. Finch Ph.D. | Co-Founder |
| Dr. William L. Klein Ph.D. | Co-Founder |
| Russell Barton M.S. | Chief Operating Officer |
| Kelly Carranza | Senior Vice President of Finance and Accounting and Corporate Controller |
| Alex Braun M.B.A. | Vice President and Head of Investor Relations |
| Derek M. Meisner Esq., J.D. | Chief Legal Officer and Corporate Secretary |
Contact
| Address | 1210-1220 Washington St., Suite 210, Newton, Massachusetts 02465, United States |
| Phone | 617 344 4190 |
| Website | https://acumenpharm.com |